Histocompatibility testing of cultivated human bone marrow stromal cells - A promising step towards pre-clinical screening for allogeneic stem cell therapy

Cellular Immunology

Volumn 259, Issue 1, 2009, Pages 61-65

  Koppula, Purushotham Reddy ^a   Chelluri, Lakshmi Kiran ^b   Polisetti, Naresh ^a   Vemuganti, Geeta K ^a  

^a L V PRASAD EYE INSTITUTE   (India)

^b Global Hospitals   (India)

Author keywords

Hypoimmunogenicity; Lineage; Mesenchymal stem cells (MSCs); MLR; MSC crossmatching; PBMNCs; Stro 1; Transdifferentiation

Indexed keywords

ALLOANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW BIOPSY; BONE MARROW CELL; CELL INTERACTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXICITY; HISTOCOMPATIBILITY TEST; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STROMA CELL; T LYMPHOCYTE ACTIVATION;

BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLS, CULTURED; CLONAL ANERGY; HISTOCOMPATIBILITY TESTING; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; PROSPECTIVE STUDIES; STROMAL CELLS;

EID: 68549117003     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.05.014     Document Type: Article

References (31)

1. Dennis J.E., and Caplan A.I. Bone marrow mesenchymal stem cells. In: Sell S. (Ed). Stem Cells Handbook (2004), Human Press, New Jersy 107-117
2. Horwitz E.M., Le Blanc K., Dominici M., et al. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7 (2005) 393-395
3. Tyndall A., Walker U.A., Cope A., et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arth. Res. Ther. 9 (2007) 301
4. Keyser K.A., Beagles K.E., Kiem H.P., et al. Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant. 16 (2007) 555-562
5. Chamberlain G., Fox J., Ashton B., et al. Mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25 (2007) 2739-2749
6. Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30 (2002) 42-48
7. Le Blanc K., Tammik L., Sundberg B., et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57 (2003) 11-20
8. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
9. Nauta A.J., and Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110 (2007) 3499-3506
10. Ryan J.M., Barry F.P., Murphy J.M., et al. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond.) 2 (2005) 8
11. Augello A., Tasso R., Negrini S.M., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35 (2005) 1482-1490
12. Krampera M., Cosmi L., Angeli R., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24 (2006) 386-398
13. Rasmusson I., Ringden O., Sundberg B., et al. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76 (2003) 1208-1213
14. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24 (2006) 74-85
15. Fox J.M., Chamberlain G., Ashton B.A., et al. Recent advances into the understanding of mesenchymal stem cell trafficking. Br. J. Haematol. 137 (2007) 491-502
16. Tse W.T., Pendleton J.D., Beyer W.M., et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003) 389-397
17. Nauta A.J., Westerhuis G., Kruisselbrink A.B., et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108 (2006) 2114-2120
18. Lakshmi Kiran A., Sahariah S., and Murthy K.J. A critical study on histocompatibility testing by serology, MLR, genotyping in renal transplantation - a single centre experience. Nephron 84 (2000) 79-80
19. Le Blanc K., Tammik C., Rosendahl K., et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31 (2003) 890-896
20. Klyushnenkova E., Mosca J.D., Zernetkina V., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 12 (2005) 47-57
21. Le Blanc K., and Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J. Intern. Med. 262 (2007) 509-525
22. Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106 (2005) 1755-1761
23. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
24. Ringden O., Uzunel M., and Rasmusson I. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397
25. Sudres M., Norol F., and Trenado A. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J. Immunol. 176 (2006) 7761-7767
26. Numaguchi Y., Sone T., Okumura K., et al. The impact of the capability of circulating progenitor cell to differentiate on myocardial salvage in patients with primary acute myocardial infarction. Circulation 114 (2006) I114-I119
27. Mazzini L., Mareschi K., Ferrero I., et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol. Res. 28 (2006) 523-526
28. Koc O.N., Day J., Nieder M., et al. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 30 (2002) 215-222
29. Tolar J., Nauta A.J., Osborn M.J., et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25 (2007) 371-379
30. Breitbach M., Bostani T., Roell W., et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110 (2007) 1362-1369
31. Polisetty N., Fatima A., Madhira S.L., et al. Mesenchymal cells from limbal stroma of human eye. Mol. Vis. 4 (2008) 431-442